Back to Search
Start Over
Comparison of efficacy and safety among axitinib, sunitinib, and sorafenib as neoadjuvant therapy for renal cell carcinoma: a retrospective study.
- Source :
-
Cancer communications (London, England) [Cancer Commun (Lond)] 2019 Oct 11; Vol. 39 (1), pp. 56. Date of Electronic Publication: 2019 Oct 11. - Publication Year :
- 2019
- Subjects :
- Adult
Aged
Antineoplastic Agents adverse effects
Axitinib adverse effects
Carcinoma, Renal Cell pathology
Female
Humans
Male
Middle Aged
Neoadjuvant Therapy adverse effects
Protein Kinase Inhibitors adverse effects
Sorafenib adverse effects
Sunitinib adverse effects
Treatment Outcome
Antineoplastic Agents therapeutic use
Axitinib therapeutic use
Carcinoma, Renal Cell drug therapy
Kidney Neoplasms drug therapy
Protein Kinase Inhibitors therapeutic use
Sorafenib therapeutic use
Sunitinib therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 2523-3548
- Volume :
- 39
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Cancer communications (London, England)
- Publication Type :
- Report
- Accession number :
- 31601263
- Full Text :
- https://doi.org/10.1186/s40880-019-0405-5